ArticleStatistics in medicine2014
Improved survival modeling in cancer research using a reduced piecewise exponential approach.
Article in Statistics in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Determining the threshold time in restricted mean survival time analysis for two group comparisons with applications in clinical and epidemiology studies.American journal of epidemiology · 2026Article
- Recurrence Incidence and Optimal Surveillance After Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Mucinous Appendix Cancer.Annals of surgical oncology · 2025Article
- Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts.Therapeutic innovation & regulatory science · 2024Article
- Lipid-Based Factors: A Promising New Biomarker for Predicting Prognosis and Conditional Survival Probability in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2022Article
- Bridged parametric survival models: General paradigm and speed improvements.Computer methods and programs in biomedicine · 2021Article
- Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.Neuro-oncology · 2021Article
- Article
- Article
- End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Future oncology (London, England) · 2017Article
- Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.Biometrics · 2017Article
- Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.NPJ breast cancer · 2016Article
- Identifying change points in a covariate effect on time-to-event analysis with reduced isotonic regression.PloS one · 2014Article
- Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival.Annals of hematology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Statistical models for survival data are typically nonparametric, for example, the Kaplan-Meier curve. Parametric survival modeling, such as exponential modeling, however, can reveal additional insights and be more efficient than nonparametric alternatives. A major constraint of the existing exponential models is the lack of flexibility due to distribution assumptions. A flexible and parsimonious piecewise exponential model is presented to best use the exponential models for arbitrary survival data. This model identifies shifts in the failure rate over time based on an exact likelihood ratio test, a backward elimination procedure, and an optional presumed order restriction on the hazard rate. Such modeling provides a descriptive tool in understanding the patient survival in addition to the Kaplan-Meier curve. This approach is compared with alternative survival models in simulation examples and illustrated in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.